 Home > Encyclopedia > Dihydroergocristine

Dihydroergocristine

Dihydroergocristine structure

CAS No:
17479-19-5
Formula:
C35H41N5O5
Chemical Name:
Dihydroergocristine
Synonyms:
Ergotaman-3′,6′,18-trione,9,10-dihydro-12′-hydroxy-2′-(1-methylethyl)-5′-(phenylmethyl)-,(5′α,10α)-;Ergocristine,9,10-dihydro-;Ergocristine,dihydro-;Indolo[4,3-fg]quinoline,ergotaman-3′,6′,18-trione deriv.;8H-Oxazolo[3,2-a]pyrrolo[2,1-c]pyrazine,ergotaman-3′,6′,18-trione deriv.;(5′α,10α)-9,10-Dihydro-12′-hydroxy-2′-(1-methylethyl)-5′-(phenylmethyl)ergotaman-3′,6′,18-trione;Dihydroergocristine;9,10-Dihydroergocristine;Dihydroergocristin;NSC 409663;11024-29-6;26913-93-9
Categories:
Pharmaceutical Intermediates > Bulk Drug Intermediates

Description

Dihydroergocristine is ergocristine in which a single bond replaces the double bond between positions 9 and 10. It is used as the mesylate salt for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. It has a role as an adrenergic antagonist and a vasodilator agent. It derives from an ergocristine. It derives from a hydride of an ergotaman.|Dihydroergocristine is part of the ergoloid mixture products. It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline. To know more about ergoloid mixtures, please visit [DB01049].|A 9,10alpha-dihydro derivative of ERGOTAMINE that contains an isopropyl sidechain at the 2' position of the molecule.

Dihydroergocristine Basic Attributes

Molecular Weight：

611.73100

Exact Mass：

611.73

EC Number：

241-493-4

UNII：

05D48LUM4Z

DSSTox ID：

DTXSID3046322

ATC Code：

C - Cardiovascular system

Characteristics

PSA：

121.70000

XLogP3：

3.37120

Density：

1.41g/cm3

Melting Point：

199 °C (decomp)

Boiling Point：

899.3ºC at 760mmHg

Flash Point：

497.7ºC

Refractive Index：

1.706

Water Solubility：

Vapor Pressure：

8.49E-35mmHg at 25°C

Safety Information

GHS Classification：

|Warning|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P301+P312, P304+P312, P304+P340, P312, P330, and P501|The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Toxicity

Toxicity Summary：

Studies related to acute and chronic toxicity as well as teratogenesis and fertility has proven that dihydroergocristine is a non-toxic and very well tolerated drug. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].

Protein Binding：

Dihydroergocristine can be found in a bound state to plasma proteins in a proportion of even 68% of the administered dose. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].

Drug Information

Drug Indication：

Dihydroergocristine is used in some countries such as Brasil as a single agent for the treatment of cerebral and peripheric vascular events. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].

Pharmacology：

Dihydroergocristine has been shown to present effect on memory and cognition. This activity in the brain is been reported by an increase in glutathione in age-related brain states. The reported effect on serotonin and adrenergic receptors has also been correlated to an inhibition of platelet aggregation. It has also been reported that individuals exposed to dihydroergocristine may present an amphoteric vasoregulating activity either hypotensive in hypertensive individuals or hypertensive in hypotensive individuals. This action is performed by promoting a dilating action in the contracted arteries and a tonic action in the dilated arteries and arterioles. The vasoregulating effect causes an increase in cerebral blood flow and oxygen consumption by the brain, which correlates with the brain protective function of dihydroergocristine. In Alzheimer studies, dihydroergocristine reduced the amyloid-beta levels in different cell types. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].

MeSH：

Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE. (See all compounds classified as Adrenergic Antagonists.)|Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)

Absorption：

Dihydroergocristine presents an absorption in the digestive tract of about 25% of the administered dose. When dihydroergocristine was orally administered in humans and the peak plasma concentration of 0.28 mcg/l was achieved after 0.46 hours. In the same report, the AUC was reported to be 0.39 mcg/l.h. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].|The most important elimination route of dihydroergocristine is in via the bile and it accounts for over 85% of the eliminated dose. Urine elimination accounts only for 5% of the administered dose. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].|Dihydroergocristine presents a large volume of distribution of 52 l/kg. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].|Dihydroergocristine presents a high systemic clearance rate of 2.65 l/h.hg. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].

Metabolism/Metabolites：

The major metabolite of dihydroergocristine is 8'-hydroxy-dihydroergocristine is produced in the liver. The modification of dihydroergocristine in the body is very extensive and it has been observed as an almost complete absence of the unchanged drug. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].

Biological Half-Life：

The half-life of dihydroergocristine has only been studied as part of the therapeutic mixture, please refer to [DB01049].

Mechanism of Action：

Dihydroergocristine mechanism of action seems to be related to a noncompetitive antagonistic activity in the serotonin receptors as well as a double partial agonist/antagonist activity in dopaminergic and adrenergic receptors. In Alzheimer studies, dihydroergocristine act as a direct inhibitor of γ-secretase.

MeSH Entry Terms：

Diertine

Computed Properties

Molecular Weight:611.7
XLogP3:3.3
Hydrogen Bond Donor Count:3
Hydrogen Bond Acceptor Count:6
Rotatable Bond Count:5
Exact Mass:611.31076943
Monoisotopic Mass:611.31076943
Topological Polar Surface Area:118
Heavy Atom Count:45
Complexity:1210
Defined Atom Stereocenter Count:7
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of Dihydroergocristine

Henan Lihao Chem Plant Limited Contact Supplier

CN
5 YRS

Business licensed

Trader Supplier of PVC resin,pvc paste resin,melamine

high purity hot sale Dihydroergocristine 99% high quality see COA KANBEI

CAS No.: 17479-19-5

Grade: Industrial Grade

Content: 99%

Inquiry